The global myelodysplastic syndrome drugs market size is expected to reach USD 5.28 billion by 2030, exhibiting at a CAGR of 9.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors such as strong product pipeline, rising geriatric population, and favorable government initiatives are driving the market.
MDS is caused by mutation of one or more genes...
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian